Novartis Ag (NVS) Cash from Operations Growth (3y) (2020 - 2026)

Novartis Ag (NVS) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Ops. Growth (3y) (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn	27.24%
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn	-18.38%
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn	13.18%
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn	18.04%
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn	-
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn	-0.88%
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn	15.19%
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn	39.10%
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn	-
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn	42.05%

Download Data